Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged
pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus …

Neutralizing antibodies can block infection, clear pathogens, and are essential to provide
long-term immunity. Since the onset of the pandemic, SARS-CoV-2 neutralizing antibodies …

The BQ and XBB subvariants of SARS-CoV-2 Omicron are now rapidly expanding, possibly
due to altered antibody evasion properties deriving from their additional spike mutations …

Continuous evolution of Omicron has led to a rapid and simultaneous emergence of
numerous variants that display growth advantages over BA. 5 (ref.). Despite their divergent …

A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant, BA.
2.86, has emerged and spread to numerous countries worldwide, raising alarm because its …

Summary Recently emerged SARS-CoV-2 Omicron subvariant, BA. 2.75, displayed a growth
advantage over circulating BA. 2.38, BA. 2.76, and BA. 5 in India. However, the underlying …

Numerous safe and effective coronavirus disease 2019 vaccines have been developed
worldwide that use various delivery technologies and engineering strategies. We show here …

Immune imprinting describes how the first exposure to a virus shapes immunological
outcomes of subsequent exposures to antigenically related strains. Severe acute respiratory …

SARS-CoV-2 continues to evolve, with many variants evading clinically authorized
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …

Effective pandemic preparedness relies on anticipating viral mutations that are able to
evade host immune responses to facilitate vaccine and therapeutic design. However, current …